

1 **Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: Protocol for a**  
2 **Randomized Controlled Trial (CanPatch).**

3 Pim Sermsaksasithorn<sup>1</sup>, Pravit Asawanonda<sup>2</sup>, Phanupong Phutrakool<sup>3</sup>, Thunnicha Ondee<sup>1</sup>, Pajaree  
4 Chariyavilaskul<sup>4</sup>, Sunchai Payungporn<sup>5</sup>, Krit Pongpirul<sup>1,6,7,8\*</sup>, Nattiya Hirankarn<sup>9\*</sup>

5 <sup>1</sup> Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,  
6 Thailand.

7 <sup>2</sup> Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,  
8 Thailand.

9 <sup>3</sup> Chulalongkorn Data Management, Research Affairs, Faculty of Medicine, Chulalongkorn University,  
10 Bangkok, Thailand.

11 <sup>4</sup> Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences,  
12 Chulalongkorn University, Bangkok, Thailand.

13 <sup>5</sup> Department of Biochemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok,  
14 Thailand.

15 <sup>6</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

16 <sup>7</sup> Department of Infection Biology & Microbiomes, Faculty of Health and Life Sciences, University of  
17 Liverpool, Liverpool, UK.

18 <sup>8</sup> Clinical and Research Center, Bumrungrad International Hospital, Bangkok, Thailand.

19 <sup>9</sup> Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

20 \* Corresponding authors: [doctorkrit@gmail.com](mailto:doctorkrit@gmail.com), [krit.po@chula.ac.th](mailto:krit.po@chula.ac.th) and [nattiya.h@chula.ac.th](mailto:nattiya.h@chula.ac.th),  
21 [nattiyap@gmail.com](mailto:nattiyap@gmail.com)

22  
23 **Funding:** The study has received financial support from the Thai Traditional Medical Knowledge Fund. The  
24 funder has no role in the design, analysis, or writing of the study.

25  
26 **Competing interests:** None.

27  
28 **Data availability:** All data relevant to the study are included in the article and supplementary documents.  
29

30 **ABSTRACT**

31

32 **Background:** Existing topical psoriasis treatments are partially effective or have long-term side effects for a  
33 proportion of people with psoriasis; therefore, effective and safe treatment options are required. Cannabidiol, a  
34 cannabinoid in *Cannabis sativa*, reverses the etiology of psoriasis through skin receptors according to in vitro  
35 research. Cannabidiol transdermal patches may be an effective treatment for psoriasis, although the efficacy and  
36 safety data are limited.

37

38 **Methods and analysis:** This is a randomized double-blind controlled trial comparing cannabidiol (CBD) with  
39 minimal tetrahydrocannabinol (THC) patches with placebo patches (1:1 ratio) daily applied to comparable  
40 lesions of each patient with mild to moderate plaque-type psoriasis performed in a university hospital in  
41 Thailand (n=60). The primary outcome is the local psoriasis severity index (LPSI). The local severity index of  
42 psoriasis, the itch score using the visual analog scale, and adverse events will be evaluated on day 0, 30, 60, and  
43 90 of the study. Furthermore, on days 0 and 90 of this study, biological samples will be taken for the evaluation  
44 of the skin, gut, and mouth microbial profile of 50% of randomly selected individuals.

45 **Conclusions:** This study aims to investigate the efficacy and safety of cannabidiol transdermal patches in  
46 alleviating the symptoms of psoriasis. We will also examine personal impacts on the efficacy and safety of  
47 patches, such as the microbial profile. The results of this study may highlight a novel topical treatment option  
48 that reduces suffering in patients with psoriasis.

49 **Ethics and dissemination:** This study was registered with the . The protocol is being considered by the  
50 Institutional Review Board of the Faculty of Medicine, Chulalongkorn University. The results of this study will  
51 be faithfully presented through conferences or published articles.

52 **Keywords:** Cannabidiol, Cannabis, Microbiota, Psoriasis, Transdermal patch

53

## 54 INTRODUCTION

55 Psoriasis is a common chronic immune-mediated systemic disease with physical, psychological, and social  
56 burden due to its disfiguring effects and substantial comorbidities, including psoriatic arthritis, metabolic  
57 diseases, inflammatory bowel disease, cardiovascular diseases, and psychiatric disorders [1-4]. The prevalence  
58 of this disease ranges from 0.27% to 11.4% in various countries and tends to increase [5, 6].

59 The pathophysiology of psoriasis is multifactorial, but the essential part is immune-mediated  
60 inflammation with IL-17 and IL-23 as key players that result in uncontrolled proliferation and dysfunctional  
61 differentiation [1, 7]. Interestingly, recent studies have shown a significant difference between the human  
62 microbiota of patients with psoriasis and the normal population, with particular genera and species of skin  
63 microbiota clearly identified on the lesional skin and disproportions of the gut microbiota that influence the  
64 pathogenesis of psoriasis via the gut-skin axis [8-16].

65 Most patients have psoriasis vulgaris or plaque-type psoriasis with mild to moderate severity; therefore,  
66 topical therapies are the treatment of choice. However, in some individuals, conventional topical therapy options  
67 are ineffective or accompanied by adverse effects [7, 17-23]. For these reasons, novel topical therapies are  
68 warranted.

69 Emerging studies in recent decades have suggested that cannabidiol (CBD), a non-addictive  
70 cannabinoid of *Cannabis sativa*, reverses the primary pathogenesis of psoriasis through various skin receptors,  
71 including inhibiting keratinocyte proliferation, reducing inflammation, modifying Th1-Th2 balance, and  
72 inhibiting IL-17 [24-36]. However, limited clinical studies have been conducted.

### 73 Cannabidiol (CBD) and psoriasis

74 Cannabinoids were found to exert opposite effects on the pathogenesis of psoriasis through skin receptors,  
75 including the CB1, CB2, GPCR55, TRPV1 and PPAR  $\gamma$  receptors [24-29, 37]. CBD, a cannabinoid derived  
76 from *Cannabis sativa* that is highly effective with minimal addictive properties, inhibits keratinocyte  
77 proliferation, reduces inflammation by inhibiting the function of NF- $\kappa$ B and TNF- $\alpha$ , modifies the balance of  
78 Th1-Th2, and alters cytokines by inhibiting IL-17 and IFN- $\gamma$  [24, 27, 28, 30, 37-42].

79 By affecting CB1, CB2, and TRP channels in cutaneous nerve fibers, mast cells, and keratinocytes,  
80 cannabinoids also reduce itching. [38, 43, 44] In clinical trials, topical use of CBD reduced itching in patients  
81 with atopic dermatitis. [45, 46]

82 CBD is added to a variety of skin products, including those for psoriasis. [34, 38]. Despite a small  
83 number of clinical research studies, the current findings of the transdermal use of CBD ointment in the treatment  
84 of psoriasis are encouraging, including a significant reduction in the Psoriasis Area Severity Index (PASI) score  
85 on day 90 and the LPSI score on week 12 after the application of CBD ointment. [30, 34, 47]

### 86 Cannabidiol (CBD) transdermal patch

87 Transdermal patches have been widely used in transdermal drug delivery systems. [48] The advantages of  
88 transdermal patches include non-invasiveness, painlessness, avoidance of first-pass metabolism, sustained  
89 medication release, and lack of gastrointestinal adverse effects [48-50]. Furthermore, transdermal patches  
90 provide better medication control and less dose variability than other transdermal drug delivery methods, such  
91 as ointments [48]. However, the lipophilic nature of cannabis makes formulation and absorption challenging for  
92 therapeutic impact, including poor skin diffusion [50-52]. Medium chain triglycerides (MCTs) have been found  
93 to be pharmaceutical carriers of lipophilic drugs [53] and used for cannabis preparation in both in vitro and in  
94 vivo studies [54-57].

### 95 Safety of Cannabidiol (CBD)

96 Cannabidiol accumulates in organs of high blood supply such as the heart, brain, liver, and lungs when it enters  
97 the body [50]. The serious adverse events of CBD are hepatocellular damage, pneumonia, cardiovascular  
98 disease, and decreased fertility [58, 59]. However, many of the damage mentioned and alterations in vitro cell  
99 viability occurred at doses of more than 200 mg/kg/day [60]. Appetite loss, diarrhea, drowsiness, and sedation  
100 are other side effects [58, 59]. Chronic CBD causes the accumulation of CBD in adipose tissue, resulting in  
101 weeks of lethargy and sedation [50]. With the topical application of CBD, previous studies have not reported  
102 serious adverse events. Minorities experience minor adverse events, including erythema, skin irritation or pain,  
103 changes in hair or skin color, somnolence, and diarrhea [31, 32, 61-66].

#### 104 **Gut, skin, and oral microbiota in psoriasis**

105 Most of the research indicated significant changes in the microbial profile in patients with psoriasis. Substantial  
106 changes in overall biodiversity, decreased  $\alpha$ -diversity, and increased  $\beta$ -diversity of the skin microbiota were  
107 discovered in psoriatic skin compared to healthy and non-lesional skin [8, 12, 67, 68]. The discovery of the  
108 hypothesis of the gut-skin axis stated that gut microbial dysbiosis leads to increased inflammatory cytokines and  
109 lessened tight junction integrity that allows blood and skin access to bacterial components and metabolite  
110 products [8, 11, 13, 15, 69, 70]. Subsequently, the studies revealed a reduction in the overall diversity of  
111 intestinal microbes and significant changes in  $\beta$ -diversity of the intestinal microbiome diversity in patients with  
112 psoriasis [15, 16, 68, 70, 71].

113 Some taxonomy of the microbiota distinguishes psoriasis from normal presentation. Compared to  
114 normal skin, the combined relative abundance of *Streptococcus spp.*, *Staphylococcus spp.* and *Corynebacterium*  
115 *spp.* increases in psoriatic skin, while the abundance of *Staphylococcus epidermidis*, *Cutibacterium acnes*, and  
116 *Cutibacterium granulosum* decreases [11, 12, 72]. The Firmicutes to Bacteroidetes ratio (F/B ratio), two main  
117 phyla of the human gut microbiota, increases in patients with psoriasis, directly correlated with PASI scores and  
118 psoriasis comorbidities [8, 13-16]. Augmentation of *Ruminococcus gnavus* increased and underrepresentation of  
119 *Faecalibacterium prausnitzii* and *Akkermansia muciniphila* were also found in the intestinal microbiota of  
120 patients with psoriasis [8-10, 13, 15, 16, 70, 73].

121 For the oral microbiome, the interaction with psoriasis pathogenesis is not well established. Compared  
122 to healthy controls, patients with psoriasis are 1.55 times more likely to develop periodontal disease, a shared  
123 mechanism involving elevated Th-17 cells and IL-17 [74]. The microbiome was distinct in the saliva of  
124 periodontal disease [75-77]. No significance was found in  $\alpha$ - or  $\beta$ -diversity of the oral microbiome of patients  
125 with psoriasis compared to normal people, although 18 species did [71].

#### 126 **OBJECTIVES AND HYPOTHESES**

127 Given the findings of a brief review of the literature showing promising therapeutic effects of CBD on psoriasis,  
128 we hypothesized that CBD with minimal transdermal patches of THC would be an effective and safe treatment  
129 option for psoriasis. Therefore, the main objective of this trial is to compare the efficacy of alleviating CBD  
130 psoriasis symptoms with minimal transdermal THC patches with placebo patches among patients with mild to  
131 moderate plaque-type psoriasis. Secondary objectives are to (1) report adverse events of CBD with minimal  
132 THC transdermal patches in patients with psoriasis (2) explore the microbial alteration of the gut, skin, and oral  
133 microbiome in patients with psoriasis who receive CBD with minimal THC transdermal patches and the  
134 relationship between the microbial profile and the clinical presentation of those patients.

#### 135 **MATERIAL AND METHODS**

##### 136 **Study design**

137 This is a randomized, double-blind, controlled study. This study is being approved by the Chulalongkorn  
138 University Faculty of Medicine Institutional Review Board (number XX) and registered with the Thai Clinical  
139 Trials Registry (TCTR No. 20220518004).

##### 140 **Participants**

141 Participants will be recruited through direct encounter and telephone contact. The participants will be from the  
142 Division of Dermatology of King Chulalongkorn Memorial Hospital's database. Furthermore, the online poster  
143 will be advertised (e.g., on Facebook). Participants in this trial will be selected based on medical history,  
144 medical records, and physical examination by physicians to verify if they meet eligibility criteria and consent  
145 forms in accordance with the research ethics requirements outlined in the Declaration of Helsinki. Inclusion and  
146 exclusion criteria are shown in **Table 1**.

147 **Table 1.** Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"><li>- Aged 18 years and older</li><li>- Have been diagnosed with mild to moderate plaque-type psoriasis with a baseline PASI score of less than ten by a board-certified dermatologist</li><li>- Have two or more plaques of psoriasis of comparable size and severity</li><li>- Refrain from using topical psoriasis therapies for at least two weeks prior to research.</li><li>- Able and willing to give written informed consent</li></ul>	<ul style="list-style-type: none"><li>- Pregnant or breastfeeding</li><li>- Have contraindications to cannabis transdermal patches (Known allergy to medical cannabis, or patches' ingredients, history of severe liver or kidney disease, history of schizophrenia or other serious psychiatric diseases)</li><li>- Addictive behavior is defined as cannabis, opioids, or other recreational or pharmaceutical drug abuser (Determined by patient interview and medical records)</li><li>- Receive biologic therapy for psoriasis treatments</li><li>- Have had less than 12 weeks of conventional systemic therapy for psoriasis (oral medications or phototherapy)</li><li>- Have received conventional systemic therapy for psoriasis (oral medications or phototherapy) for more than 12 weeks but have seen variations in psoriasis symptoms or adjustments in their medication or phototherapy regimen within the past 12 weeks</li></ul>

148

#### 149 **Study medication**

150 Intervention patches (P patches) will include  $1.0 \pm 0.1$  mg of CBD in an MCT solvent on  $2.0 \pm 0.2$  g of yellow  
151 adhesive layer covered with aluminum foil whereas placebo control patches (C patches) will be 2.0 g of yellow  
152 adhesive layer covered with aluminum foil.

#### 153 **Procedures**

154 All participants who meet the eligibility criteria and provide their written consent are invited to respond to the  
155 baseline demographic and clinical characteristics. For each participant, two similar psoriasis lesions are selected  
156 and then randomly assigned to the intervention plaque or the control plaque in a 1:1 ratio. An overview of the  
157 progress of the current trial is shown in the consolidated standards of reporting trials diagram (**Figure 1**). The  
158 study and control participants are instructed to apply a P or C patch, respectively, on a selected plaque of  
159 psoriasis every day for 90 days and at least 6 hours a day.

#### 160 **Adherence**

161 Face-to-face reminder sessions are conducted at initial product dispensing and three subsequent visits. This  
162 session reviews the application of transdermal patches, including scheduling, storage, and missing dosage  
163 solutions. At each follow-up appointment, unused patches and used patches' packages are tallied and  
164 documented.

#### 165 **Randomization**

166 Two similar psoriasis lesions of each patient are randomly assigned to the intervention group or control group  
167 by block randomization with a ratio 1: 1 with blocks of 4 by STATA version 15.0 (StataCorp. 2017. Stata  
168 Statistical Software: Release 15. College Station, TX: StataCorp LLC.).

#### 169 Blinding

170 After double-blind randomization, individuals not involved in the study translate the randomization code into  
171 instructions on which patches should be used on which lesion. They place the instructions in sealed envelopes  
172 that are then delivered to patients randomly by a physician. Each lesion is instructed in the same type of patch  
173 every day. The front of an opaque sealed envelope is the study ID and the date the envelope will be opened.  
174 Therefore, patients and physicians are blinded. Allocation concealment is ensured, as the service will not release  
175 the randomization code until data collection has been completed. A code might be broken in extraordinary cases  
176 where knowledge of the actual therapy is vital for future patient care.

#### 177 Trial sites

178 Division of Dermatology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok,  
179 Thailand.

#### 180 Biological sample collection for genetic analysis

181 Biological sample collection includes 1 ml of saliva and a spoon of feces collected by participants in separate  
182 containers prepared by researchers and skin samples from three regions, two lesional skin samples, and one  
183 sample of nonlesional skin collected by skin taping by physicians. The five containers per individual containing  
184 nucleic acid preservation buffer will be transported to the laboratory in 30 minutes at room temperature or as  
185 soon as possible at 4 degrees Celsius. Upon arrival at the laboratory of the Faculty of Medicine, Chulalongkorn  
186 University, the sample will be extracted by Quick-DNA™ H M W MagBead Kit (cat. no. D6060, Zymo  
187 Research) and then amplified by the PCR method. The PCR amplification products will be purified by AMPure  
188 XP (Beckman Coulter) and the quantity will be measured by NanoPhotometer® C40 (Implen, USA). After that,  
189 DNA will be combined with the solution for the Ligation Sequencing Kit (LSK-109, Oxford Nanopore  
190 Technologies) to perform DNA sequencing using the Nanopore MinION sequencing system. All samples will  
191 be recorded and barcoded with a unique storage ID.

#### 192 Data collection and management

193 Data collection in this study is based on personal characteristics, clinical evaluations, and self-reported  
194 measures. Baseline demographic and clinical characteristics include age (years), sex, weight, body mass index  
195 (BMI), familial history of psoriasis, duration of psoriasis, comorbidities (diabetes mellitus, hypertension,  
196 dyslipidemia, obesity, metabolic syndrome, cardiovascular disease, psoriatic arthritis, inflammatory bowel  
197 disease, psychiatric disorders, among others) and concurrent therapies for systemic psoriasis. The local psoriasis  
198 severity index (LPSI), self-reported itching on the visual analog scale, reported adverse events, and microbial  
199 profile are collected at the time points below.

200 All investigators will have access to the final trial data set. All documents will be safely stored in the  
201 Skin Unit Research Facilities for Academic and Clinical Excellence (SURFACE), Division of Dermatology,  
202 Department of Medicine, Faculty of Medicine, Chulalongkorn University, for ten years. No identifiable data  
203 will be recorded and all documents will be recorded with the research identification number.

#### 204 Outcome measures

205 Evaluations are collected at four time points: 0<sup>th</sup>, 30<sup>th</sup>, 60<sup>th</sup> and 90<sup>th</sup> day of the study. Fifty percent of the  
206 participants are chosen at random to have their saliva, feces, and skin samples collected if they consent to the  
207 storage and future testing of biological materials. An overview of all the assessment points and results is shown  
208 in **Table 2**.

209 **Table 2.** SPIRIT Schedule for enrollment, interventions, and assessments.

210

	Enrolment	Allocation	Intervention			Close-out
TIMEPOINT**	0	0	30 <sup>th</sup>	60 <sup>th</sup>	90 <sup>th</sup>	120 <sup>th</sup>
<b>ENROLMENT:</b>						213
Eligibility screen	X					214
Informed consent	X					215
Collect demographics and baseline clinical data	X					216
Collect a biological sample	O				O	217
Allocation		X				218
<b>INTERVENTIONS:</b>						219
[Intervention group]						220
[Control group]						221
<b>ASSESSMENTS:</b>						222
Local Psoriasis Severity Index	X		X	X	X	223
Reported adverse events			X	X	X	224
Demographics and baseline clinical data	X					225
Microbial profile						226

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

O = Fifty percent of the participants were randomly chosen to collect saliva, feces and skin samples.

242 *asis severity index (LPSI)*

243 Each lesion will be assessed with a modified psoriasis area severity index called the local psoriasis severity  
 244 index (LPSI). The LPSI is the sum of the following symptoms evaluated by the physician: erythema (redness),  
 245 induration (thickness) and desquamation (scaling infiltration). Each score was classified as follows: 0 = no  
 246 symptoms, 1 = slight symptoms, 2 = moderate symptoms, 3 = marked symptoms, 4 = very marked symptoms  
 247 [78]. P.A., a dermatology professor, conducts all LPSI evaluations for this study.

248 Secondary outcome measure

249 *The itch score by the visual analog scale*

250 The visual analog scale consists of a line 10 cm long, with verbal anchors at either end. The patient places a  
 251 mark on the line corresponding to the patient's intensity rating. VAS is one of the most commonly used methods  
 252 for assessing the severity of pruritus, as it provides an easy, rapid and valid estimate of the itch [79-81].  
 253 Participants will be asked to indicate the point within three minutes of this study.

254 *The alpha-diversity, beta-diversity, and relative abundance of microbiota*

255 Biological samples, including saliva, feces, and skin, will be analyzed for microbial alteration in the form of  
256 microbial diversity. The diversity of microbes will be defined as the proportion and abundance distribution of  
257 different types of organism. The abundance distribution includes alpha diversity, which is an abundance of  
258 different bacterial taxa in a single sample, and beta diversity, which is microbial diversity in different samples.  
259 Relative abundance is the ratio of the absolute abundance of a taxon to the total absolute abundance of all taxa  
260 in a unit volume of an ecosystem. [8, 82, 83]

#### 261 **Reporting of adverse events**

262 Participants are encouraged to contact research staff if they have concerns about mental or physical health  
263 decline. Upon the occurrence of an adverse event, the patient would receive treatment for the adverse event at  
264 King Chulalongkorn Memorial Hospital for free.

#### 265 **Discontinuation and withdrawal**

266 Patients who experience major adverse effects after enrolling in the study, participate less than 80% of the  
267 research period, or are unwilling to continue participating in the trial will be excluded. However, the data  
268 already collected and the reason for the cessation of study participation may be included in the final report.

#### 269 **STATISTICAL ANALYSIS**

270 Sample size calculation

271 This study compares the mean LPSI score of transdermal CBD and placebo use. With the 80% power,  $\alpha = 0.05$ ,  
272 effect size 0.58, and allocation ratio 1:1, the determined sample size per group is 48 individuals. However, there  
273 is a potential for around 20% of the individuals to drop out of the study. The researchers determine that the total  
274 sample size is 60 individuals.

#### 275 **Statistical method**

276 Statistical analysis will be performed using STATA version 15.0 (StataCorp. 2017. Stata Statistical Software:  
277 Release 15. College Station, TX: StataCorp LLC.). Categorical data will be expressed as a number and  
278 depending on which is more appropriate, continuous data will be reported as mean +/- standard deviation or  
279 median +/- interquartile range. Qualitative variables will be presented in a table and then analyzed by the Chi-  
280 square test or Fisher's exact test. The paired T-test or the unpaired T-test will be applied for quantitative data  
281 with normal distribution. The Wilcoxon signed ranks test or Mann-Whitney U test will be used for the  
282 quantitative data, which is not present with normal distribution.

#### 283 **Sequencing and Microbiome data analysis**

284 The taxonomic classification will be assigned for the V3/V4 16S region. All taxonomic classifications will be  
285 implemented within QIIME2. Bacterial diversity is determined by alpha diversity and beta diversity, which will  
286 be calculated by the QIIME 2 pipeline. Alpha diversity will be analyzed using Shannon's diversity and  
287 Simpson's diversity. Beta diversity will be analyzed by Bray-Curtis dissimilarity.

#### 288 **TRIAL STATUS AND TIMELINE**

289 The research will be advertised from April 2023 to May 2023. Subsequently, subject recruitment will occur  
290 from May 2023 to June 2023. The duration of the intervention will be between July 2023 and September 2023.  
291 Data analysis will be conducted from September 2023 to December 2023. The presentation of the data and the  
292 preparation of the manuscript will be completed by January 2024.

#### 293 **DISCUSSION**



294 This study will be the first randomized controlled study to assess the efficacy and safety of CBD-containing  
295 transdermal patches with minimal THC in patients with mild to moderate plaque-type psoriasis. It will also be  
296 the first to investigate the correlation of the baseline and alteration of the microbial profile and the efficacy and  
297 safety of CBD with minimal THC patches, which can help with customized patches, in addition to age, sex,  
298 BMI, and genetic variables. If the intervention shows significant positive results, the promise of minimal THC  
299 transdermal CBD patches as an alternative topical therapy option for psoriasis sufferers will be emphasized, and  
300 additional studies on a larger scale may be conducted on this issue. Further research could examine (i) the  
301 efficacy and cost-effectiveness compared to the standard of care, (ii) barriers to implementation (e.g. social  
302 stigma, cost of administration, and legalization policies)

303 The strengths of this study include (i) a double-blind randomized design, (ii) a review of the aspects of  
304 the patients and physicians of the psoriasis symptoms, (iv) transdermal patches that could better control the  
305 amount of CBD than the previous form of transdermal CBD administration, and (v) investigation of  
306 personalized factors that include the microbial profile and demographic and clinical characteristics. However,  
307 this study also has several limitations including (i) recruiting and providing intervention at a single site and in an  
308 academic medical center setting that could limit generalizability and (ii) the subjective nature of the itch score,  
309 which includes individual variation. The study results will be released to the participating physicians, patients,  
310 and the general medical community. For reproducible research, we will transfer a collection of entirely  
311 anonymized data to a suitable data archive for sharing purposes. Any protocol amendment will be approved by  
312 the Institutional Review Board of Chulalongkorn University and the Thai Clinical Trials Registry prior to  
313 implementation.

#### 314 **Authors' contributions**

315 PS, KP, PA, PP, SV, TO, and SC conceived of the study and initiated the study design. PS wrote original draft.  
316 PS, KP, PA, and PP review and edit the draft. KP and PA supervised. PP provided statistical expertise in clinical  
317 trial design and primary statistical analysis. All authors contributed to the refinement of the study protocol and  
318 approved the final manuscript.

#### 319 **Acknowledgements**

320 None.

#### 321 **Supporting Information**

322 Supplementary 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related  
323 documents.

#### 324 **References**

- 325 1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. *Lancet* (London, England).  
326 2021;397(10281):1301-15. Epub 2021/04/05. doi: 10.1016/s0140-6736(20)32549-6. PubMed PMID:  
327 33812489.
- 328 2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *Journal of*  
329 *the European Academy of Dermatology and Venereology : JEADV*. 2017;31(2):205-12. Epub 2016/08/31.  
330 doi: 10.1111/jdv.13854. PubMed PMID: 27573025.
- 331 3. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. *Dermatologic therapy*. 2010;23(2):114-  
332 8. Epub 2010/04/27. doi: 10.1111/j.1529-8019.2010.01304.x. PubMed PMID: 20415817.
- 333 4. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. *Anais*  
334 *brasileiros de dermatologia*. 2015;90(1):9-20. Epub 2015/02/13. doi: 10.1590/abd1806-4841.20153038.  
335 PubMed PMID: 25672294; PubMed Central PMCID: PMC4323693.
- 336 5. Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM. Systematic review examining changes over time and  
337 variation in the incidence and prevalence of psoriasis by age and gender. *The British journal of*  
338 *dermatology*. 2021;184(2):243-58. Epub 2020/05/03. doi: 10.1111/bjd.19169. PubMed PMID: 32358790.
- 339 6. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional,  
340 and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ (Clinical research*  
341 *ed)*. 2020;369:m1590. Epub 2020/05/30. doi: 10.1136/bmj.m1590. PubMed PMID: 32467098; PubMed  
342 Central PMCID: PMC7254147.

- 343 7. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. *International journal of molecular sciences*.  
344 2019;20(6). Epub 2019/03/27. doi: 10.3390/ijms20061475. PubMed PMID: 30909615; PubMed Central  
345 PMCID: PMC6471628.
- 346 8. Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A.  
347 Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. *International journal of*  
348 *molecular sciences*. 2021;22(8). Epub 2021/05/01. doi: 10.3390/ijms22083998. PubMed PMID: 33924414;  
349 PubMed Central PMCID: PMC68069836.
- 350 9. Chen G, Chen ZM, Fan XY, Jin YL, Li X, Wu SR, et al. Gut-Brain-Skin Axis in Psoriasis: A Review.  
351 *Dermatology and therapy*. 2021;11(1):25-38. Epub 2020/11/19. doi: 10.1007/s13555-020-00466-9.  
352 PubMed PMID: 33206326; PubMed Central PMCID: PMC68759123.
- 353 10. Chen L, Li J, Zhu W, Kuang Y, Liu T, Zhang W, et al. Skin and Gut Microbiome in Psoriasis: Gaining  
354 Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies. *Frontiers in*  
355 *microbiology*. 2020;11:589726. Epub 2021/01/02. doi: 10.3389/fmicb.2020.589726. PubMed PMID:  
356 33384669; PubMed Central PMCID: PMC67769758.
- 357 11. De Francesco MA, Caruso A. The Gut Microbiome in Psoriasis and Crohn's Disease: Is Its Perturbation a  
358 Common Denominator for Their Pathogenesis? *Vaccines*. 2022;10(2). Epub 2022/02/27. doi:  
359 10.3390/vaccines10020244. PubMed PMID: 35214702; PubMed Central PMCID: PMC68877283.
- 360 12. Ferček I, Lugović-Mihić L, Tambić-Andrašević A, Česić D, Grginić AG, Bešlić I, et al. Features of the  
361 Skin Microbiota in Common Inflammatory Skin Diseases. *Life (Basel, Switzerland)*. 2021;11(9). Epub  
362 2021/09/29. doi: 10.3390/life11090962. PubMed PMID: 34575111; PubMed Central PMCID:  
363 PMC68468136.
- 364 13. Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A, et al. Gut Microbiome in  
365 Psoriasis: An Updated Review. *Pathogens (Basel, Switzerland)*. 2020;9(6). Epub 2020/06/18. doi:  
366 10.3390/pathogens9060463. PubMed PMID: 32545459; PubMed Central PMCID: PMC67350295.
- 367 14. Kieraszińska M, Donskow-Lysoniewska K. Both the microbiome and the macrobiome can influence  
368 immune responsiveness in psoriasis. *Central-European journal of immunology*. 2021;46(4):502-8. Epub  
369 2022/02/08. doi: 10.5114/ceji.2021.110314. PubMed PMID: 35125950; PubMed Central PMCID:  
370 PMC68808298.
- 371 15. Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut  
372 Microbiome-Current State of Art. *International journal of molecular sciences*. 2021;22(9). Epub  
373 2021/05/01. doi: 10.3390/ijms22094529. PubMed PMID: 33926088; PubMed Central PMCID:  
374 PMC68123672.
- 375 16. Colucci R, Moretti S. Implication of Human Bacterial Gut Microbiota on Immune-Mediated and  
376 Autoimmune Dermatological Diseases and Their Comorbidities: A Narrative Review. *Dermatology and*  
377 *therapy*. 2021;11(2):363-84. Epub 2021/01/29. doi: 10.1007/s13555-021-00485-0. PubMed PMID:  
378 33507493; PubMed Central PMCID: PMC68018919.
- 379 17. Le Roux E, Frow H. Diagnosis and management of mild to moderate psoriasis. *Prescriber*. 2020;31(7-8):9-  
380 17. doi: <https://doi.org/10.1002/psb.1855>.
- 381 18. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.  
382 *Jama*. 2020;323(19):1945-60. Epub 2020/05/20. doi: 10.1001/jama.2020.4006. PubMed PMID: 32427307.
- 383 19. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for  
384 patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What  
385 constitutes a clinically significant improvement when treating psoriasis? *Journal of the American Academy*  
386 *of Dermatology*. 2000;43(2 Pt 1):281-5. Epub 2000/07/25. doi: 10.1067/mjd.2000.106374. PubMed PMID:  
387 10906652.
- 388 20. Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, et al. Psoriasis Prevalence and  
389 Severity by Expert Elicitation. *Dermatology and therapy*. 2021;11(3):1053-64. Epub 2021/04/23. doi:  
390 10.1007/s13555-021-00518-8. PubMed PMID: 33886086; PubMed Central PMCID: PMC68163919.
- 391 21. Chiricozzi A, Pimpinelli N, Ricceri F, Bagnoni G, Bartoli L, Bellini M, et al. Treatment of psoriasis with  
392 topical agents: Recommendations from a Tuscany Consensus. *Dermatologic therapy*. 2017;30(6). Epub  
393 2017/09/25. doi: 10.1111/dth.12549. PubMed PMID: 28940579.
- 394 22. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. *Canadian family physician*  
395 *Medecin de famille canadien*. 2017;63(4):278-85. Epub 2017/04/14. PubMed PMID: 28404701; PubMed  
396 Central PMCID: PMC65389757.
- 397 23. Kessler TR. Treating patients with moderate-to-severe psoriasis vulgaris. *JAAPA : official journal of the*  
398 *American Academy of Physician Assistants*. 2022;35(3):28-35. Epub 2022/02/05. doi:  
399 10.1097/01.JAA.0000819580.10133.b1. PubMed PMID: 35120363.
- 400 24. Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic Potential of  
401 Cannabidiol (CBD) for Skin Health and Disorders. *Clinical, cosmetic and investigational dermatology*.

- 402 2020;13:927-42. Epub 2020/12/19. doi: 10.2147/ccid.S286411. PubMed PMID: 33335413; PubMed  
403 Central PMCID: PMCPCMC7736837.
- 404 25. Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin.  
405 A potential approach for the treatment of skin disorders. *Biochemical pharmacology*. 2018;157:122-33.  
406 Epub 2018/08/24. doi: 10.1016/j.bcp.2018.08.022. PubMed PMID: 30138623.
- 407 26. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-  
408 CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. *Journal of*  
409 *dermatological science*. 2007;45(2):87-92. Epub 2006/12/13. doi: 10.1016/j.jdermsci.2006.10.009.  
410 PubMed PMID: 17157480.
- 411 27. Ramot Y, Sugawara K, Zákány N, Tóth BI, Bíró T, Paus R. A novel control of human keratin expression:  
412 cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in  
413 human keratinocytes in vitro and in situ. *PeerJ*. 2013;1:e40. Epub 2013/05/03. doi: 10.7717/peerj.40.  
414 PubMed PMID: 23638377; PubMed Central PMCID: PMCPCMC3628749.
- 415 28. Norooznehad AH, Norooznehad F. Cannabinoids: Possible agents for treatment of psoriasis via  
416 suppression of angiogenesis and inflammation. *Medical hypotheses*. 2017;99:15-8. Epub 2017/01/24. doi:  
417 10.1016/j.mehy.2016.12.003. PubMed PMID: 28110689.
- 418 29. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory  
419 drugs. *Future medicinal chemistry*. 2009;1(7):1333-49. Epub 2010/03/02. doi: 10.4155/fmc.09.93. PubMed  
420 PMID: 20191092; PubMed Central PMCID: PMCPCMC2828614.
- 421 30. Palmieri B, Laurino C, Vadalà M. A therapeutic effect of cbd-enriched ointment in inflammatory skin  
422 diseases and cutaneous scars. *La Clinica terapeutica*. 2019;170(2):e93-e9. Epub 2019/04/18. doi:  
423 10.7417/ct.2019.2116. PubMed PMID: 30993303.
- 424 31. Tijani AO, Thakur D, Mishra D, Frempong D, Chukwunyere UI, Puri A. Delivering therapeutic  
425 cannabinoids via skin: Current state and future perspectives. *Journal of controlled release : official journal*  
426 *of the Controlled Release Society*. 2021;334:427-51. Epub 2021/05/09. doi: 10.1016/j.jconrel.2021.05.005.  
427 PubMed PMID: 33964365.
- 428 32. Mahmood F, Lim MM, Kirchoff MG. A Survey of Topical Cannabis Use in Canada. *Journal of cutaneous*  
429 *medicine and surgery*. 2022;26(2):156-61. Epub 2021/11/21. doi: 10.1177/12034754211059025. PubMed  
430 PMID: 34798780.
- 431 33. Yeroushalmi S, Nelson K, Sparks A, Friedman A. Perceptions and recommendation behaviors of  
432 dermatologists for medical cannabis: A pilot survey. *Complementary therapies in medicine*.  
433 2020;55:102552. Epub 2020/11/22. doi: 10.1016/j.ctim.2020.102552. PubMed PMID: 33220620.
- 434 34. Martins AM, Gomes AL, Vilas Boas I, Marto J, Ribeiro HM. Cannabis-Based Products for the Treatment  
435 of Skin Inflammatory Diseases: A Timely Review. *Pharmaceuticals (Basel, Switzerland)*. 2022;15(2).  
436 Epub 2022/02/27. doi: 10.3390/ph15020210. PubMed PMID: 35215320; PubMed Central PMCID:  
437 PMCPCMC8878527.
- 438 35. Tammaro A, Magri F, Chello C, Giordano D, Parisella FR, De Marco G, et al. A successful topical  
439 treatment for cutaneous inflammatory diseases: an additional or alternative therapy to topical steroids.  
440 *European annals of allergy and clinical immunology*. 2019;51(3):129-30. Epub 2019/05/14. doi:  
441 10.23822/EurAnnACI.1764-1489.79. PubMed PMID: 31081604.
- 442 36. Yeroushalmi S, Nemirovsky D, Mamlouk M, Feldman D, Nelson K, Sparks A, et al. Consumer  
443 Perspectives on and Utilization of Medical Cannabis to Treat Dermatologic Conditions. *Journal of drugs in*  
444 *dermatology : JDD*. 2022;21(1):31-6. Epub 2022/01/11. doi: 10.36849/jdd.2022.6540. PubMed PMID:  
445 35005866.
- 446 37. Sheriff T, Lin MJ, Dubin D, Khorasani H. The potential role of cannabinoids in dermatology. *The Journal*  
447 *of dermatological treatment*. 2020;31(8):839-45. Epub 2019/10/11. doi: 10.1080/09546634.2019.1675854.  
448 PubMed PMID: 31599175.
- 449 38. Jhawar N, Schoenberg E, Wang JV, Saedi N. The growing trend of cannabidiol in skincare products.  
450 *Clinics in dermatology*. 2019;37(3):279-81. Epub 2019/06/11. doi: 10.1016/j.clindermatol.2018.11.002.  
451 PubMed PMID: 31178109.
- 452 39. Martinelli G, Magnavacca A, Fumagalli M, Dell'Agli M, Piazza S, Sangiovanni E. Cannabis sativa and  
453 Skin Health: Dissecting the Role of Phytocannabinoids. *Planta medica*. 2022;88(7):492-506. Epub  
454 2021/04/15. doi: 10.1055/a-1420-5780. PubMed PMID: 33851375.
- 455 40. Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the  
456 "C(ut)annabinoid" System. *Molecules (Basel, Switzerland)*. 2019;24(5). Epub 2019/03/09. doi:  
457 10.3390/molecules24050918. PubMed PMID: 30845666; PubMed Central PMCID: PMCPCMC6429381.
- 458 41. Osafo N, Yeboah OK, Antwi AO. Endocannabinoid system and its modulation of brain, gut, joint and skin  
459 inflammation. *Molecular biology reports*. 2021;48(4):3665-80. Epub 2021/04/29. doi: 10.1007/s11033-  
460 021-06366-1. PubMed PMID: 33909195.

- 461 42. Namazi MR. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition.  
462 Journal of the European Academy of Dermatology and Venereology : JEADV. 2005;19(3):319-22. Epub  
463 2005/04/29. doi: 10.1111/j.1468-3083.2004.01184.x. PubMed PMID: 15857457.
- 464 43. Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic  
465 pruritus: A review. Journal of the American Academy of Dermatology. 2020;82(5):1205-12. Epub  
466 2020/01/29. doi: 10.1016/j.jaad.2020.01.036. PubMed PMID: 31987788.
- 467 44. Makhakhe L. Topical cannabidiol (CBD) in skin pathology - A comprehensive review and prospects for  
468 new therapeutic opportunities. South African family practice : official journal of the South African  
469 Academy of Family Practice/Primary Care. 2022;64(1):e1-e4. Epub 2022/06/14. doi:  
470 10.4102/safp.v64i1.5493. PubMed PMID: 35695447; PubMed Central PMCID: PMCPMC9210160.
- 471 45. Maghfour J, Rietcheck HR, Rundle CW, Runion TM, Jafri ZA, Dercon S, et al. An Observational Study of  
472 the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin. Journal of drugs in dermatology :  
473 JDD. 2020;19(12):1204-8. Epub 2020/12/22. doi: 10.36849/jdd.2020.5464. PubMed PMID: 33346512.
- 474 46. Maghfour J, Rundle CW, Rietcheck HR, Dercon S, Lio P, Mamo A, et al. Assessing the effects of topical  
475 cannabidiol in patients with atopic dermatitis. Dermatology online journal. 2021;27(2). Epub 2021/04/06.  
476 PubMed PMID: 33818989.
- 477 47. Puaratanaarunkon T, Sittisaksomjai S, Sivapornpan N, Pongcharoen P, Chakkavittumrong P, Ingkaninan  
478 K, et al. Topical cannabidiol-based treatment for psoriasis: A dual-centre randomized placebo-controlled  
479 study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2022;36(9):e718-  
480 e20. Epub 2022/05/11. doi: 10.1111/jdv.18215. PubMed PMID: 35536599.
- 481 48. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and  
482 pharmacology. British journal of pharmacology. 2015;172(9):2179-209. Epub 2015/01/07. doi:  
483 10.1111/bph.13059. PubMed PMID: 25560046; PubMed Central PMCID: PMCPMC4403087.
- 484 49. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and  
485 opportunities in dermal/transdermal delivery. Therapeutic delivery. 2010;1(1):109-31. Epub 2010/12/07.  
486 doi: 10.4155/tde.10.16. PubMed PMID: 21132122; PubMed Central PMCID: PMCPMC2995530.
- 487 50. Lucas CJ, Galetti P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids.  
488 British journal of clinical pharmacology. 2018;84(11):2477-82. Epub 2018/07/13. doi: 10.1111/bcp.13710.  
489 PubMed PMID: 30001569; PubMed Central PMCID: PMCPMC6177698.
- 490 51. Junaid MSA, Tijani AO, Puri A, Banga AK. In vitro percutaneous absorption studies of cannabidiol using  
491 human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils.  
492 International journal of pharmaceutics. 2022;616:121540. Epub 2022/02/07. doi:  
493 10.1016/j.ijpharm.2022.121540. PubMed PMID: 35124116.
- 494 52. Tanner, Marks R. Delivering drugs by the transdermal route: review and comment. Skin research and  
495 technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and]  
496 International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging  
497 (ISSI). 2008;14(3):249-60. Epub 2009/01/23. doi: 10.1111/j.1600-0846.2008.00316.x. PubMed PMID:  
498 19159369.
- 499 53. Ramella A, Roda G, Pavlovic R, Cas MD, Casagni E, Mosconi G, et al. Impact of Lipid Sources on  
500 Quality Traits of Medical Cannabis-Based Oil Preparations. Molecules (Basel, Switzerland). 2020;25(13).  
501 Epub 2020/07/08. doi: 10.3390/molecules25132986. PubMed PMID: 32629796; PubMed Central PMCID:  
502 PMCPMC7412533.
- 503 54. Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical cannabis for the  
504 treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of  
505 biochemical safety. Frontiers in pharmacology. 2022;13:977484. Epub 2022/10/18. doi:  
506 10.3389/fphar.2022.977484. PubMed PMID: 36249785; PubMed Central PMCID: PMCPMC9559854.
- 507 55. Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive  
508 improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-  
509 stage, phase 2 clinical trial. Communications medicine. 2022;2(1):139. Epub 2022/11/10. doi:  
510 10.1038/s43856-022-00202-8. PubMed PMID: 36352103; PubMed Central PMCID: PMCPMC9628346.
- 511 56. Tonoyan L, Babu D, Reiz B, Le T, Siraki AG. Heating of consumer cannabis oils can lead to free radical  
512 initiated degradation, causing CBD and THC depletion. Free radical biology & medicine. 2022;192:77-83.  
513 Epub 2022/09/17. doi: 10.1016/j.freeradbiomed.2022.09.005. PubMed PMID: 36113706.
- 514 57. Feng W, Qin C, Cipolla E, Lee JB, Zgair A, Chu Y, et al. Inclusion of Medium-Chain Triglyceride in  
515 Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo  
516 Performance Remains Superior with Pure Sesame Oil Vehicle. Pharmaceutics. 2021;13(9). Epub  
517 2021/09/29. doi: 10.3390/pharmaceutics13091349. PubMed PMID: 34575426; PubMed Central PMCID:  
518 PMCPMC8472830.
- 519 58. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a  
520 systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology : official

- 521 publication of the American College of Neuropsychopharmacology. 2020;45(11):1799-806. Epub  
522 2020/04/09. doi: 10.1038/s41386-020-0667-2. PubMed PMID: 32268347; PubMed Central PMCID:  
523 PMCPMC7608221.
- 524 59. Meissner H, Cascella M. Cannabidiol (CBD). StatPearls. Treasure Island (FL): StatPearls Publishing  
525 Copyright © 2022, StatPearls Publishing LLC.; 2022.
- 526 60. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and  
527 Toxicity. *Current neuropharmacology*. 2019;17(10):974-89. Epub 2019/06/05. doi:  
528 10.2174/1570159x17666190603171901. PubMed PMID: 31161980; PubMed Central PMCID:  
529 PMCPMC7052834.
- 530 61. Maghfour J, Rietcheck H, Szeto MD, Rundle CW, Sivesind TE, Dellavalle RP, et al. Tolerability profile of  
531 topical cannabidiol and palmitoylethanolamide: a compilation of single-centre randomized evaluator-  
532 blinded clinical and in vitro studies in normal skin. *Clinical and experimental dermatology*.  
533 2021;46(8):1518-29. Epub 2021/05/23. doi: 10.1111/ced.14749. PubMed PMID: 34022073.
- 534 62. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief  
535 of Peripheral Neuropathy of the Lower Extremities. *Current pharmaceutical biotechnology*.  
536 2020;21(5):390-402. Epub 2019/12/04. doi: 10.2174/1389201020666191202111534. PubMed PMID:  
537 31793418.
- 538 63. Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis-based medicines - A novel paradigm and  
539 treatment for non-uremic calciphylaxis leg ulcers: An open label trial. *International wound journal*.  
540 2020;17(5):1508-16. Epub 2020/09/03. doi: 10.1111/iwj.13484. PubMed PMID: 32875692; PubMed  
541 Central PMCID: PMCPMC7540661.
- 542 64. Yin HY, Hadjokas N, Mirchia K, Swan R, Alpert S. Commercial Cannabinoid Oil-Induced Stevens-  
543 Johnson Syndrome. Case reports in ophthalmological medicine. 2020;2020:6760272. Epub 2020/03/10.  
544 doi: 10.1155/2020/6760272. PubMed PMID: 32148986; PubMed Central PMCID: PMCPMC7053463.
- 545 65. Scheffer IE, Hulihan J, Messenheimer J, Ali S, Keenan N, Griesser J, et al. Safety and Tolerability of  
546 Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A  
547 Nonrandomized Controlled Trial. *JAMA network open*. 2021;4(9):e2123930. Epub 2021/09/04. doi:  
548 10.1001/jamanetworkopen.2021.23930. PubMed PMID: 34477852; PubMed Central PMCID:  
549 PMCPMC8417764.
- 550 66. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment  
551 of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric  
552 fragile X syndrome. *Journal of neurodevelopmental disorders*. 2019;11(1):16. Epub 2019/08/03. doi:  
553 10.1186/s11689-019-9277-x. PubMed PMID: 31370779; PubMed Central PMCID: PMCPMC6676516.
- 554 67. Habeebuddin M, Karnati RK, Shiroorkar PN, Nagaraja S, Asdaq SMB, Khalid Anwer M, et al. Topical  
555 Probiotics: More Than a Skin Deep. *Pharmaceutics*. 2022;14(3). Epub 2022/03/27. doi:  
556 10.3390/pharmaceutics14030557. PubMed PMID: 35335933; PubMed Central PMCID:  
557 PMCPMC8955881.
- 558 68. Damiani G, Bragazzi NL, McCormick TS, Pigatto PDM, Leone S, Pacifico A, et al. Gut microbiota and  
559 nutrient interactions with skin in psoriasis: A comprehensive review of animal and human studies. *World  
560 journal of clinical cases*. 2020;8(6):1002-12. Epub 2020/04/08. doi: 10.12998/wjcc.v8.i6.1002. PubMed  
561 PMID: 32258071; PubMed Central PMCID: PMCPMC7103976.
- 562 69. Le ST, Toussi A, Maverakis N, Marusina AI, Barton VR, Merleev AA, et al. The cutaneous and intestinal  
563 microbiome in psoriatic disease. *Clinical immunology (Orlando, Fla)*. 2020;218:108537. Epub 2020/07/18.  
564 doi: 10.1016/j.clim.2020.108537. PubMed PMID: 32679247.
- 565 70. Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut-skin axis. *Clinics in dermatology*.  
566 2021;39(5):829-39. Epub 2021/11/18. doi: 10.1016/j.clinidermatol.2021.08.021. PubMed PMID:  
567 34785010.
- 568 71. Todberg T, Kaiser H, Zachariae C, Egeberg A, Halling AS, Skov L. Characterization of the Oral and Gut  
569 Microbiota in Patients with Psoriatic Diseases: A Systematic Review. *Acta dermato-venereologica*.  
570 2021;101(7):adv00512. Epub 2021/07/16. doi: 10.2340/00015555-3882. PubMed PMID: 34263334.
- 571 72. Carmona-Cruz S, Orozco-Covarrubias L, Sáez-de-Ocariz M. The Human Skin Microbiome in Selected  
572 Cutaneous Diseases. *Frontiers in cellular and infection microbiology*. 2022;12:834135. Epub 2022/03/25.  
573 doi: 10.3389/fcimb.2022.834135. PubMed PMID: 35321316; PubMed Central PMCID:  
574 PMCPMC8936186.
- 575 73. Eppinga H, Sperma Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, et al.  
576 Similar Depletion of Protective *Faecalibacterium prausnitzii* in Psoriasis and Inflammatory Bowel Disease,  
577 but not in Hidradenitis Suppurativa. *Journal of Crohn's & colitis*. 2016;10(9):1067-75. Epub 2016/03/14.  
578 doi: 10.1093/ecco-jcc/jjw070. PubMed PMID: 26971052.

- 579 74. Zorba M, Melidou A, Patsatsi A, Ioannou E, Kolokotronis A. The possible role of oral microbiome in  
580 autoimmunity. *International journal of women's dermatology*. 2020;6(5):357-64. Epub 2021/04/27. doi:  
581 10.1016/j.ijwd.2020.07.011. PubMed PMID: 33898698; PubMed Central PMCID: PMCPMC8060669.
- 582 75. Curtis MA, Diaz PI, Van Dyke TE. The role of the microbiota in periodontal disease. *Periodontology*  
583 2000. 2020;83(1):14-25. Epub 2020/05/10. doi: 10.1111/prd.12296. PubMed PMID: 32385883.
- 584 76. Costalonga M, Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and  
585 caries. *Immunology letters*. 2014;162(2 Pt A):22-38. Epub 2014/12/03. doi: 10.1016/j.imlet.2014.08.017.  
586 PubMed PMID: 25447398; PubMed Central PMCID: PMCPMC4346134.
- 587 77. Vieira Colombo AP, Magalhães CB, Hartenbach FA, Martins do Souto R, Maciel da Silva-Boghossian C.  
588 Periodontal-disease-associated biofilm: A reservoir for pathogens of medical importance. *Microbial*  
589 *pathogenesis*. 2016;94:27-34. Epub 2015/09/30. doi: 10.1016/j.micpath.2015.09.009. PubMed PMID:  
590 26416306.
- 591 78. Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue  
592 light in the treatment of psoriasis vulgaris. *Dermatology (Basel, Switzerland)*. 2011;223(3):251-9. Epub  
593 2011/11/23. doi: 10.1159/000333364. PubMed PMID: 22105015.
- 594 79. Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation  
595 of the instrument for the assessment of pruritus. *Acta dermato-venereologica*. 2012;92(5):497-501. Epub  
596 2011/11/22. doi: 10.2340/00015555-1265. PubMed PMID: 22102095.
- 597 80. Lazaridou A, Elbaridi N, Edwards RR, Berde CB. Chapter 5 - Pain Assessment. In: Benzon HT, Raja SN,  
598 Liu SS, Fishman SM, Cohen SP, editors. *Essentials of Pain Medicine (Fourth Edition)*: Elsevier; 2018. p.  
599 39-46.e1.
- 600 81. Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective  
601 study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale  
602 in 471 patients with chronic pruritus. *Acta dermato-venereologica*. 2012;92(5):502-7. Epub 2011/12/16.  
603 doi: 10.2340/00015555-1246. PubMed PMID: 22170091.
- 604 82. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207-14. Epub  
605 2012/06/16. doi: 10.1038/nature11234. PubMed PMID: 22699609; PubMed Central PMCID:  
606 PMCPMC3564958.
- 607 83. Lin H, Peddada SD. Analysis of microbial compositions: a review of normalization and differential  
608 abundance analysis. *NPJ biofilms and microbiomes*. 2020;6(1):60. Epub 2020/12/04. doi: 10.1038/s41522-  
609 020-00160-w. PubMed PMID: 33268781; PubMed Central PMCID: PMCPMC7710733.

610

**Figure 1. CONSORT flow diagram** flowchart of phases of Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: A Randomized Controlled Trial (CanPatch)

